FACULTY

John W. Devlin, PharmD, BCPS, FCCM, FCCP
Associate Professor
Director, Critical Care Pharmacy Fellowship Program
Northeastern University
Bouvé College of Health Sciences
Boston, Massachusetts

BIOGRAPHY
John W. Devlin, PharmD, BCPS, FCCM, FCCP, is an Associate Professor of Pharmacy at Northeastern University, an Adjunct Associate Professor of Medicine at Tufts University, and a Clinical Pharmacist in the medical ICU at Tufts Medical Center in Boston, MA. Dr. Devlin has published more than 80 peer-reviewed papers and textbook chapters and presented more than 75 research abstracts - most of which pertain to various areas of critical care pharmacotherapy. He is a member of the editorial board of both Critical Care Medicine and Pharmacotherapy. His research is primarily focused on the detection and treatment of delirium in the ICU and the use and assessment of sedation in the critically ill.

ACCREDITATION STATEMENT
Pharmacy
The France Foundation is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and will award 0.1 CEU to pharmacists who participate in this activity and complete the registration and evaluation forms. There is no fee to participate in this activity. This is an application-based activity.
UAN: 0391-0000-10-003-H01-P.

Credits: 1.0 hours (0.10 ceu)

TYPE OF ACTIVITY: Application

TECHNICAL REQUIREMENTS: Adobe Presenter

Media: Webcast

Estimated time to complete activity: Estimated time to complete this activity is 30 minutes.

PROCEDURE

To obtain CME credit:

1. Review the activity objectives and CE information.
2. Complete the CE activity.
3. Complete the posttest. A score of at least 70% is required to successfully complete this activity.
4. Complete the CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
5. Your CE certificate will be available for download after you submit the completed evaluation form.

Approximately 3 months after submitting your outcomes survey, you will receive an e-mail invitation to respond to a very short follow-up online survey, which will allow us to verify your continued understanding and application of the information presented in this educational activity. Please plan to take a moment to respond to the follow-up survey.

TARGET AUDIENCE
This activity is intended for hospital pharmacists who manage patients requiring sedation in intensive care and perioperative settings.

EDUCATIONAL NEEDS
Patients in intensive care or undergoing procedures frequently require pain management. Assessment of pain, sedation, agitation, and delirium with validated scales is a critical part of maintaining the balance between oversedation and undersedation. Practical application of recent results from patient management trials and from pharmaceutical clinical trials can enhance the practice of sedation and patient outcomes.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, the participants should be able to:

1. Manage adult patients who need sedation and analgesia while receiving ventilator support according to current standards and guidelines
2. Use validated scales for sedation, pain, agitation, and delirium in the management of these critically ill patients
3. Assess recent clinical findings in sedation and analgesia management and incorporate them into the management of patients in the acute care and procedural sedation settings.

Disclosure
It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME/CE committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures
The following faculty have indicated they have relationships with industry to disclose relative to the content of this CME/CE activity:

• John Devlin, PharmD, BCPS, FCCM, FCCP has received grant/research support from AstraZeneca and Hospira. He has served as a consultant for Hospira.

Unapproved Use Disclosure
The France Foundation requires CE faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Hospira assume no liability for the information herein.